Journal
CANCER LETTERS
Volume 338, Issue 1, Pages 158-167Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.05.028
Keywords
Osteosarcoma; Cancer stem cell; Tumor initiating cell; Mesenchymal tumors; Bone cancer; Sox2; FGF; Wnt signaling
Categories
Funding
- NIAMS [AR051358]
- NIDCR [DE013745]
- St. Baldrick's Research Award
- Children's Cancer Research Fund
Ask authors/readers for more resources
Osteosarcoma is an aggressive pediatric tumor of growing bones that, despite surgery and chemotherapy, is prone to relapse. These mesenchymal tumors are derived from progenitor cells in the osteoblast lineage that have accumulated mutations to escape cell cycle checkpoints leading to excessive proliferation and defects in their ability to differentiate appropriately into mature bone-forming osteoblasts. Like other malignant tumors, osteosarcoma is often heterogeneous, consisting of phenotypically distinct cells with features of different stages of differentiation. The cancer stem cell hypothesis posits that tumors are maintained by stem cells and it is the incomplete eradication of a refractory population of tumor-initiating stem cells that accounts for drug resistance and tumor relapse. In this review we present our current knowledge about the biology of osteosarcoma stem cells from mouse and human tumors, highlighting new insights and unresolved issues in the identification of this elusive population. We focus on factors and pathways that are implicated in maintaining such cells, and differences from paradigms of epithelial cancers. Targeting of the cancer stem cells in osteosarcoma is a promising avenue to explore to develop new therapies for this devastating childhood cancer. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available